Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year-long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine-albendazole.
Identifieur interne : 003627 ( PubMed/Corpus ); précédent : 003626; suivant : 003628Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year-long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine-albendazole.
Auteurs : J A Rizzo ; C. Belo ; R. Lins ; G. DreyerSource :
- Annals of tropical medicine and parasitology [ 0003-4983 ] ; 2007.
English descriptors
- KwdEn :
- Adolescent, Adult, Albendazole (adverse effects), Albendazole (therapeutic use), Animals, Anthelmintics (adverse effects), Anthelmintics (therapeutic use), Brazil (epidemiology), Child, Diethylcarbamazine (adverse effects), Diethylcarbamazine (therapeutic use), Drug Therapy, Combination, Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (epidemiology), Elephantiasis, Filarial (parasitology), Female, Filaricides (adverse effects), Filaricides (therapeutic use), Humans, Male, Prevalence, Treatment Outcome, Wuchereria bancrofti.
- MESH :
- chemical , adverse effects : Albendazole, Anthelmintics, Diethylcarbamazine, Filaricides.
- chemical , therapeutic use : Albendazole, Anthelmintics, Diethylcarbamazine, Filaricides.
- geographic , epidemiology : Brazil.
- drug therapy : Elephantiasis, Filarial.
- epidemiology : Elephantiasis, Filarial.
- parasitology : Elephantiasis, Filarial.
- Adolescent, Adult, Animals, Child, Drug Therapy, Combination, Female, Humans, Male, Prevalence, Treatment Outcome, Wuchereria bancrofti.
Abstract
In filariasis-endemic areas beyond sub-Saharan Africa, the World Health Organization's recommended strategy for interrupting transmission of the causative parasites is annual, single-dose, mass treatment with a combination of diethylcarbamazine (DEC; given at 6 mg/kg) and albendazole (ALB; given at 400 mg) for 4-6 years (the minimum estimated life-span of the adult parasites). In an open, hospital-based, randomized and controlled trial, with a blinded evaluation of outcome, 82 children and adolescents from Recife, all with Wuchereria bancrofti microfilaraemias, were given either DEC alone (6 mg/kg) or the same dose of DEC combined with ALB (at 400 mg/patient). Every 90 days for 1 year after the single treatment, each patient was checked for microfilaraemia by the filtration of up to 5 ml of venous blood collected at night. One year post-treatment, 16 (39%) of the 41 patients given DEC alone and 20 (49%) of the 41 given DEC-ALB were found microfilaraemic (relative risk=0.8, with a 95% confidence interval of 0.49-1.31) and the corresponding geometric mean levels of microfilaraemia were 2.0% and 1.8% of the levels recorded immediately pre-treatment, respectively (P>0.05). In terms of the prevalences and intensities of microfilaraemia, therefore, the addition of ALB to the DEC appeared to offer no significant benefit.
DOI: 10.1179/136485907X176517
PubMed: 17550648
Links to Exploration step
pubmed:17550648Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year-long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine-albendazole.</title><author><name sortKey="Rizzo, J A" sort="Rizzo, J A" uniqKey="Rizzo J" first="J A" last="Rizzo">J A Rizzo</name><affiliation><nlm:affiliation>Centro de Pesquisas em Alergia e Imunologia Clínica, Ambulatório de Alergia, Hospital das Clínicas, Universidade Federal de Pernambuco, Avenida Moraes Rego s/n, Cidade Universitária, CEP 50740-900, Recife, PE, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Belo, C" sort="Belo, C" uniqKey="Belo C" first="C" last="Belo">C. Belo</name></author><author><name sortKey="Lins, R" sort="Lins, R" uniqKey="Lins R" first="R" last="Lins">R. Lins</name></author><author><name sortKey="Dreyer, G" sort="Dreyer, G" uniqKey="Dreyer G" first="G" last="Dreyer">G. Dreyer</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:17550648</idno><idno type="pmid">17550648</idno><idno type="doi">10.1179/136485907X176517</idno><idno type="wicri:Area/PubMed/Corpus">003627</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003627</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year-long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine-albendazole.</title><author><name sortKey="Rizzo, J A" sort="Rizzo, J A" uniqKey="Rizzo J" first="J A" last="Rizzo">J A Rizzo</name><affiliation><nlm:affiliation>Centro de Pesquisas em Alergia e Imunologia Clínica, Ambulatório de Alergia, Hospital das Clínicas, Universidade Federal de Pernambuco, Avenida Moraes Rego s/n, Cidade Universitária, CEP 50740-900, Recife, PE, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Belo, C" sort="Belo, C" uniqKey="Belo C" first="C" last="Belo">C. Belo</name></author><author><name sortKey="Lins, R" sort="Lins, R" uniqKey="Lins R" first="R" last="Lins">R. Lins</name></author><author><name sortKey="Dreyer, G" sort="Dreyer, G" uniqKey="Dreyer G" first="G" last="Dreyer">G. Dreyer</name></author></analytic><series><title level="j">Annals of tropical medicine and parasitology</title><idno type="ISSN">0003-4983</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Albendazole (adverse effects)</term><term>Albendazole (therapeutic use)</term><term>Animals</term><term>Anthelmintics (adverse effects)</term><term>Anthelmintics (therapeutic use)</term><term>Brazil (epidemiology)</term><term>Child</term><term>Diethylcarbamazine (adverse effects)</term><term>Diethylcarbamazine (therapeutic use)</term><term>Drug Therapy, Combination</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (epidemiology)</term><term>Elephantiasis, Filarial (parasitology)</term><term>Female</term><term>Filaricides (adverse effects)</term><term>Filaricides (therapeutic use)</term><term>Humans</term><term>Male</term><term>Prevalence</term><term>Treatment Outcome</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Albendazole</term><term>Anthelmintics</term><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Albendazole</term><term>Anthelmintics</term><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Brazil</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="parasitology" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Animals</term><term>Child</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Prevalence</term><term>Treatment Outcome</term><term>Wuchereria bancrofti</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In filariasis-endemic areas beyond sub-Saharan Africa, the World Health Organization's recommended strategy for interrupting transmission of the causative parasites is annual, single-dose, mass treatment with a combination of diethylcarbamazine (DEC; given at 6 mg/kg) and albendazole (ALB; given at 400 mg) for 4-6 years (the minimum estimated life-span of the adult parasites). In an open, hospital-based, randomized and controlled trial, with a blinded evaluation of outcome, 82 children and adolescents from Recife, all with Wuchereria bancrofti microfilaraemias, were given either DEC alone (6 mg/kg) or the same dose of DEC combined with ALB (at 400 mg/patient). Every 90 days for 1 year after the single treatment, each patient was checked for microfilaraemia by the filtration of up to 5 ml of venous blood collected at night. One year post-treatment, 16 (39%) of the 41 patients given DEC alone and 20 (49%) of the 41 given DEC-ALB were found microfilaraemic (relative risk=0.8, with a 95% confidence interval of 0.49-1.31) and the corresponding geometric mean levels of microfilaraemia were 2.0% and 1.8% of the levels recorded immediately pre-treatment, respectively (P>0.05). In terms of the prevalences and intensities of microfilaraemia, therefore, the addition of ALB to the DEC appeared to offer no significant benefit.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17550648</PMID><DateCreated><Year>2007</Year><Month>06</Month><Day>06</Day></DateCreated><DateCompleted><Year>2007</Year><Month>11</Month><Day>13</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-4983</ISSN><JournalIssue CitedMedium="Print"><Volume>101</Volume><Issue>5</Issue><PubDate><Year>2007</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Annals of tropical medicine and parasitology</Title><ISOAbbreviation>Ann Trop Med Parasitol</ISOAbbreviation></Journal><ArticleTitle>Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year-long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine-albendazole.</ArticleTitle><Pagination><MedlinePgn>423-33</MedlinePgn></Pagination><Abstract><AbstractText>In filariasis-endemic areas beyond sub-Saharan Africa, the World Health Organization's recommended strategy for interrupting transmission of the causative parasites is annual, single-dose, mass treatment with a combination of diethylcarbamazine (DEC; given at 6 mg/kg) and albendazole (ALB; given at 400 mg) for 4-6 years (the minimum estimated life-span of the adult parasites). In an open, hospital-based, randomized and controlled trial, with a blinded evaluation of outcome, 82 children and adolescents from Recife, all with Wuchereria bancrofti microfilaraemias, were given either DEC alone (6 mg/kg) or the same dose of DEC combined with ALB (at 400 mg/patient). Every 90 days for 1 year after the single treatment, each patient was checked for microfilaraemia by the filtration of up to 5 ml of venous blood collected at night. One year post-treatment, 16 (39%) of the 41 patients given DEC alone and 20 (49%) of the 41 given DEC-ALB were found microfilaraemic (relative risk=0.8, with a 95% confidence interval of 0.49-1.31) and the corresponding geometric mean levels of microfilaraemia were 2.0% and 1.8% of the levels recorded immediately pre-treatment, respectively (P>0.05). In terms of the prevalences and intensities of microfilaraemia, therefore, the addition of ALB to the DEC appeared to offer no significant benefit.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rizzo</LastName><ForeName>J A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Centro de Pesquisas em Alergia e Imunologia Clínica, Ambulatório de Alergia, Hospital das Clínicas, Universidade Federal de Pernambuco, Avenida Moraes Rego s/n, Cidade Universitária, CEP 50740-900, Recife, PE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belo</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Lins</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Dreyer</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Trop Med Parasitol</MedlineTA><NlmUniqueID>2985178R</NlmUniqueID><ISSNLinking>0003-4983</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000871">Anthelmintics</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005369">Filaricides</NameOfSubstance></Chemical><Chemical><RegistryNumber>F4216019LN</RegistryNumber><NameOfSubstance UI="D015766">Albendazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>V867Q8X3ZD</RegistryNumber><NameOfSubstance UI="D004049">Diethylcarbamazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015766" MajorTopicYN="N">Albendazole</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000871" MajorTopicYN="N">Anthelmintics</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004049" MajorTopicYN="N">Diethylcarbamazine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000469" MajorTopicYN="N">parasitology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005369" MajorTopicYN="N">Filaricides</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014958" MajorTopicYN="Y">Wuchereria bancrofti</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>11</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17550648</ArticleId><ArticleId IdType="doi">10.1179/136485907X176517</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003627 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003627 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:17550648
|texte= Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year-long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine-albendazole.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:17550648" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |